You searched for "refractive"
The lived experience of benign essential blepharospasm
Benign essential blepharospasm (BEB) is a rare neurological condition which causes involuntary sustained or intermittent muscular contraction of both eyelids and upper facial muscles which cause closure of eyelids, abnormal facial expressions and distress [1]. The term dystonia is an...
Aqueous humour cytokine levels in PCV and nAMD
This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...
Fenofibrate and diabetic retinopathy
Fenofibrate is an agonist of peroxisome proliferator-activated receptor-alpha (PPARα) which is used as a lipid-lowering agent. By reducing blood lipid levels, it can decrease retinal hard exudates which is beneficial in diabetic retinopathy (DR). FIELD and ACCORD studies show that...Obtaining US clinical experience in ophthalmology as a UK medical student or junior doctor
Medical students or junior doctors in the UK may be interested in gaining US clinical experience for many reasons. Unfortunately, many trainees do not know how to arrange these and there is a common misconception that it is difficult to...Streamlining cataract lists: how are you managing it?
Mr Jonathan Ross, in conversation with Ms Bita Manzouri, provides a personal perspective on challenges and opportunities shaping the future of cataract surgery services across the hospital eye service. Redesigning cataract pathways in response to COVID-19 Bita Manzouri: Over the...Serendipity
“Serendipity is looking in a haystack for a needle and discovering a farmer’s daughter” – Julius Comroe Jr (Surgeon, Medical Researcher and Author) One of the attractive features of ophthalmology, apart from the good quality of life and the relatively...Intravitreal injections delivered by ophthalmic clinical nurse specialists
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...
